2. Search Result
Search Result
Results for "

α4 integrin

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

6

Peptides

7

Inhibitory Antibodies

2

Natural
Products

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3533
    EILEVPST

    		Integrin Cardiovascular Disease
    EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .
    EILEVPST
  • HY-70073
    Zaurategrast
    2 Publications Verification

    CT7758

    		 Integrin Inflammation/Immunology
    Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor .
    Zaurategrast
  • HY-14857
    Carotegrast

    HCA2969

    		 Integrin Inflammation/Immunology
    Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities.
    Carotegrast
  • HY-124290
    Carotegrast methyl

    AJM300

    		 Integrin Inflammation/Immunology
    Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice .
    Carotegrast methyl
  • HY-P9911A
    Vedolizumab (anti-α4β7-integrin)

    		Integrin Inflammation/Immunology
    Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
    Vedolizumab (anti-α4β7-integrin)
  • HY-P9911
    Vedolizumab
    1 Publications Verification

    Anti-Human lymphocyte α4β7 integrin, Humanized Antibody

    		 Integrin Inflammation/Immunology Cancer
    Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
    Vedolizumab
  • HY-134130
    Integrin modulator 1

    		Integrin Inflammation/Immunology
    Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM .
    Integrin modulator 1
  • HY-P2267
    LDV
    1 Publications Verification

    		 Integrin Others
    LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .
    LDV
  • HY-159179
    α4 integrin receptor antagonist 3

    		Integrin Inflammation/Immunology
    α4 integrin receptor antagonist 3 (Compound 11) is an orally active α4integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between α4β1/VCAM-1 and α4β7/MAdCAM-1, with IC50 values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model .
    α4 integrin receptor antagonist 3
  • HY-124290A
    Carotegrast methyl hydrochloride

    AJM300 hydrochloride

    		 Integrin Inflammation/Immunology
    Carotegrast methyl (AJM300) hydrochloride is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl hydrochloride, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl hydrochloride prevents the development of colitis in mice .
    Carotegrast methyl hydrochloride
  • HY-123802
    BIO7662

    		Integrin Cancer
    BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .
    BIO7662
  • HY-75385
    Zaurategrast ethyl ester

    CDP323; UCB1184197

    		 Integrin Inflammation/Immunology
    Zaurategrast ethyl ester (CDP323), the ethyl ester proagent of CT7758 , is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders .
    Zaurategrast ethyl ester
  • HY-138542
    RO0270608

    		Integrin Inflammation/Immunology
    RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activity .
    RO0270608
  • HY-75385A
    Zaurategrast ethyl ester sulfate

    CDP323 sulfate; UCB1184197 sulfate

    		 Integrin Inflammation/Immunology
    Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester proagent of CT7758 , is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders .
    Zaurategrast ethyl ester sulfate
  • HY-136214
    R-BC154 acetate

    		Integrin Inflammation/Immunology Cancer
    R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity .
    R-BC154 acetate
  • HY-P1188
    LDV-FITC

    		Integrin Cancer
    LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
    LDV-FITC
  • HY-14951
    Firategrast
    Maximum Cited Publications
    6 Publications Verification

    SB 683699

    		 Integrin Neurological Disease
    Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
    Firategrast
  • HY-P1188A
    LDV-FITC TFA

    		Integrin Cancer
    LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
    LDV-FITC TFA
  • HY-15770
    TR-14035
    4 Publications Verification

    		 Integrin Inflammation/Immunology
    TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
    TR-14035
  • HY-P99184
    Abrilumab

    		Integrin Infection Inflammation/Immunology Cancer
    Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
    Abrilumab
  • HY-107589A
    BIO5192 hydrate
    1 Publications Verification

    		 Integrin Inflammation/Immunology
    BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .
    BIO5192 hydrate
  • HY-107589
    BIO5192
    1 Publications Verification

    		 Integrin Inflammation/Immunology
    BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .
    BIO5192
  • HY-129453
    BOP sodium

    		Integrin Inflammation/Immunology
    BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .
    BOP sodium
  • HY-108831
    Natalizumab
    2 Publications Verification

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
    Natalizumab
  • HY-14189
    Valategrast hydrochloride

    R-411

    		 Integrin Inflammation/Immunology
    Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
    Valategrast hydrochloride
  • HY-P9984
    Etrolizumab
    2 Publications Verification

    rhuMAb Beta7; RG7413; PRO145223

    		 Integrin Cancer
    Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
    Etrolizumab
  • HY-108831A
    Natalizumab (Solution)
    2 Publications Verification

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
    Natalizumab (Solution)
  • HY-14190
    Valategrast

    R-411 free base

    		 Integrin Inflammation/Immunology
    Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
    Valategrast
  • HY-P3522
    REDV

    		Integrin Cancer
    REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .
    REDV
  • HY-P3522A
    REDV TFA

    		Integrin Cancer
    REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .
    REDV TFA
  • HY-N2587
    Irigenin

    		Integrin Apoptosis Cancer
    Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .
    Irigenin
  • HY-N2587R
    Irigenin (Standard)

    		Integrin Apoptosis Cancer
    Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .
    Irigenin (Standard)
  • HY-122585
    proMMP-9 inhibitor-3c

    		MMP Src FAK Cancer
    proMMP-9 inhibitor-3c (compound 3c) is a potent proMMP-9 inhibitor. proMMP-9 inhibitor-3c is specific for binding to the proMMP-9 hemopexin-like domain (Kd=320 nM). proMMP-9 inhibitor-3c disruption of MMP-9 homodimerization prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR. This disruption results in decreased phosphorylation of Src and its downstream target proteins focal adhesion kinase (FAK) and paxillin (PAX) .
    proMMP-9 inhibitor-3c

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: